Log in
NASDAQ:CNMD

CONMED Competitors

$82.89
-1.58 (-1.87 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$80.72
Now: $82.89
$83.93
50-Day Range
$73.29
MA: $82.00
$88.59
52-Week Range
$37.66
Now: $82.89
$116.81
Volume248,448 shs
Average Volume364,723 shs
Market Capitalization$2.37 billion
P/E Ratio87.25
Dividend Yield0.95%
Beta0.56

Competitors

CONMED (NASDAQ:CNMD) Vs. ABT, MDT, ISRG, SYK, BDX, and BSX

Should you be buying CNMD stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to CONMED, including Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), and Boston Scientific (BSX).

Abbott Laboratories (NYSE:ABT) and CONMED (NASDAQ:CNMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Abbott Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, CONMED has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Institutional & Insider Ownership

73.1% of Abbott Laboratories shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 4.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dividends

Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. CONMED pays out 30.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Abbott Laboratories and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.30%8.32%
CONMED3.00%11.18%4.43%

Analyst Recommendations

This is a breakdown of recent recommendations for Abbott Laboratories and CONMED, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
CONMED02402.67

Abbott Laboratories currently has a consensus price target of $115.1250, suggesting a potential upside of 5.62%. CONMED has a consensus price target of $98.00, suggesting a potential upside of 18.23%. Given CONMED's higher possible upside, analysts plainly believe CONMED is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Abbott Laboratories and CONMED's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.05$3.69 billion$3.2433.64
CONMED$955.10 million2.48$28.62 million$2.6431.40

Abbott Laboratories has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Abbott Laboratories beats CONMED on 11 of the 15 factors compared between the two stocks.

Medtronic (NYSE:MDT) and CONMED (NASDAQ:CNMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Medtronic has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, CONMED has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Medtronic and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
CONMED3.00%11.18%4.43%

Institutional & Insider Ownership

79.9% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 4.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Medtronic and CONMED's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.02$4.79 billion$4.5923.51
CONMED$955.10 million2.48$28.62 million$2.6431.40

Medtronic has higher revenue and earnings than CONMED. Medtronic is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Medtronic and CONMED, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132212.85
CONMED02402.67

Medtronic currently has a consensus price target of $117.8571, suggesting a potential upside of 9.20%. CONMED has a consensus price target of $98.00, suggesting a potential upside of 18.23%. Given CONMED's higher possible upside, analysts plainly believe CONMED is more favorable than Medtronic.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Medtronic pays out 50.5% of its earnings in the form of a dividend. CONMED pays out 30.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Medtronic beats CONMED on 12 of the 17 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

CONMED has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Profitability

This table compares CONMED and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED3.00%11.18%4.43%
Intuitive Surgical24.45%12.08%10.44%

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. 4.4% of CONMED shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CONMED and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million2.48$28.62 million$2.6431.40
Intuitive Surgical$4.48 billion18.68$1.38 billion$9.9571.53

Intuitive Surgical has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED02402.67
Intuitive Surgical381202.39

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Intuitive Surgical has a consensus target price of $720.4737, suggesting a potential upside of 1.22%. Given CONMED's stronger consensus rating and higher possible upside, research analysts clearly believe CONMED is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats CONMED on 10 of the 14 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Stryker (NYSE:SYK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility and Risk

CONMED has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares CONMED and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED3.00%11.18%4.43%
Stryker11.38%20.53%8.89%

Institutional & Insider Ownership

71.0% of Stryker shares are held by institutional investors. 4.4% of CONMED shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CONMED and Stryker's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million2.48$28.62 million$2.6431.40
Stryker$14.88 billion5.41$2.08 billion$8.2626.00

Stryker has higher revenue and earnings than CONMED. Stryker is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED02402.67
Stryker291612.57

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Stryker has a consensus target price of $220.68, suggesting a potential upside of 2.77%. Given CONMED's stronger consensus rating and higher possible upside, research analysts clearly believe CONMED is more favorable than Stryker.

Dividends

CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.1%. CONMED pays out 30.3% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Stryker beats CONMED on 15 of the 18 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility and Risk

CONMED has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Profitability

This table compares CONMED and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED3.00%11.18%4.43%
Becton, Dickinson and5.30%14.19%5.86%

Institutional & Insider Ownership

84.2% of Becton, Dickinson and shares are held by institutional investors. 4.4% of CONMED shares are held by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CONMED and Becton, Dickinson and's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million2.48$28.62 million$2.6431.40
Becton, Dickinson and$17.29 billion4.06$1.23 billion$11.6820.72

Becton, Dickinson and has higher revenue and earnings than CONMED. Becton, Dickinson and is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Becton, Dickinson and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED02402.67
Becton, Dickinson and07712.60

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Becton, Dickinson and has a consensus target price of $280.8571, suggesting a potential upside of 16.06%. Given CONMED's stronger consensus rating and higher possible upside, research analysts clearly believe CONMED is more favorable than Becton, Dickinson and.

Dividends

CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.3%. CONMED pays out 30.3% of its earnings in the form of a dividend. Becton, Dickinson and pays out 27.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Becton, Dickinson and beats CONMED on 13 of the 17 factors compared between the two stocks.

CONMED (NASDAQ:CNMD) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

CONMED has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares CONMED and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED3.00%11.18%4.43%
Boston Scientific39.18%12.86%5.76%

Insider & Institutional Ownership

90.2% of Boston Scientific shares are owned by institutional investors. 4.4% of CONMED shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares CONMED and Boston Scientific's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million2.48$28.62 million$2.6431.40
Boston Scientific$10.74 billion4.91$4.70 billion$1.5823.33

Boston Scientific has higher revenue and earnings than CONMED. Boston Scientific is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CONMED and Boston Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED02402.67
Boston Scientific031833.00

CONMED presently has a consensus target price of $98.00, suggesting a potential upside of 18.23%. Boston Scientific has a consensus target price of $44.6522, suggesting a potential upside of 21.14%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than CONMED.

Summary

Boston Scientific beats CONMED on 12 of the 15 factors compared between the two stocks.


CONMED Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
1.8$109.00-1.1%$190.85 billion$31.90 billion57.67Earnings Announcement
Analyst Revision
Medtronic logo
MDT
Medtronic
2.1$107.93-3.2%$145.08 billion$28.91 billion33.01
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.5$711.77-3.3%$83.67 billion$4.48 billion81.07
Stryker logo
SYK
Stryker
1.9$214.74-3.3%$80.49 billion$14.88 billion51.01Upcoming Earnings
Becton, Dickinson and logo
BDX
Becton, Dickinson and
1.7$242.00-0.7%$69.65 billion$17.29 billion87.05
Boston Scientific logo
BSX
Boston Scientific
2.1$36.86-0.8%$53.18 billion$10.74 billion13.07Upcoming Earnings
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$78.08-3.0%$48.55 billion$4.35 billion67.12Earnings Announcement
Insider Selling
Analyst Revision
Baxter International logo
BAX
Baxter International
2.0$80.01-1.3%$41.05 billion$11.36 billion24.17Upcoming Earnings
DexCom logo
DXCM
DexCom
1.5$418.00-1.7%$40.02 billion$1.48 billion190.87
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.2$428.96-0.2%$36.49 billion$2.41 billion81.09Upcoming Earnings
Heavy News Reporting
ResMed logo
RMD
ResMed
1.6$180.53-1.4%$26.16 billion$2.96 billion42.28Upcoming Earnings
Hologic logo
HOLX
Hologic
1.9$68.66-1.1%$17.78 billion$3.37 billion27.80Analyst Upgrade
Insulet logo
PODD
Insulet
1.4$253.53-1.6%$16.64 billion$738.20 million905.50
Teleflex logo
TFX
Teleflex
1.5$357.36-2.5%$16.62 billion$2.60 billion35.17Upcoming Earnings
Steris logo
STE
Steris
1.7$186.42-0.6%$15.86 billion$3.03 billion38.76Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.2$172.46-0.1%$15.68 billion$3.23 billion56.18
Masimo logo
MASI
Masimo
1.2$246.04-0.5%$13.52 billion$937.84 million63.74
ABIOMED logo
ABMD
ABIOMED
1.2$288.32-2.4%$12.68 billion$840.88 million83.09Upcoming Earnings
Hill-Rom logo
HRC
Hill-Rom
1.9$91.51-1.0%$6.10 billion$2.91 billion29.52
Globus Medical logo
GMED
Globus Medical
1.8$53.77-0.2%$5.26 billion$785.37 million62.52Upcoming Earnings
Integra LifeSciences logo
IART
Integra LifeSciences
1.5$47.47-3.4%$4.00 billion$1.52 billion-1,582.33Upcoming Earnings
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$30.62-0.1%$3.97 billion$920.90 million-28.89Heavy News Reporting
NuVasive logo
NUVA
NuVasive
1.6$50.93-2.8%$2.61 billion$1.17 billion-424.42Upcoming Earnings
Integer logo
ITGR
Integer
1.7$64.95-2.1%$2.13 billion$1.26 billion29.52Upcoming Earnings
AtriCure logo
ATRC
AtriCure
1.6$37.25-1.9%$1.71 billion$230.81 million-28.87
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$38.76-0.8%$1.57 billion$236.54 million-49.69Heavy News Reporting
Alphatec logo
ATEC
Alphatec
1.6$8.89-7.3%$741.24 million$113.43 million-7.94
CryoLife logo
CRY
CryoLife
2.2$18.96-2.0%$732.17 million$276.22 million-63.20
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$33.06-1.3%$638.98 million$459.95 million-28.02
Surmodics logo
SRDX
Surmodics
1.4$39.80-2.8%$541.52 million$100.08 million71.07Upcoming Earnings
Analyst Downgrade
AngioDynamics logo
ANGO
AngioDynamics
2.3$11.00-0.6%$420.14 million$264.16 million-2.48
Accuray logo
ARAY
Accuray
1.5$3.06-1.3%$282.71 million$382.93 million102.00Upcoming Earnings
Invacare logo
IVC
Invacare
1.4$7.18-0.3%$247.13 million$927.96 million-5.70Upcoming Earnings
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.92-4.3%$64.89 million$61.30 million-2.05
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.